Heron Therapeutics reported $-2.95M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
ALKERMES USD 16.29M 15.79M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 35.15M 10.44M Sep/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
Eisai JPY 11.69B 6.55B Sep/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Ligand Pharmaceuticals USD -28.48M 76.99M Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Omeros USD -32.23M 23.81M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Veracyte USD 31.5M 6.01M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026